Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 5/20 | 0.60 |
| ▸ | ITGAV | P06756 | 5/20 | 0.60 |
| ▸ | ABCG2 | Q9UNQ0 | 14/20 | 0.37 |
| ▸ | ABCC1 | P33527 | 4/20 | 0.35 |
| ▸ | ABCB1 | P08183 | 5/20 | 0.35 |
| ▸ | NCF1 | P14598 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21100765 | 0.96 | ITGB3 (0.60) | ITGB3ITGAVABCG2ABCC1ABCB1 | |
| SCHEMBL21100766 | 0.96 | ITGB3 (0.64) | ITGB3ITGAVABCG2ABCC1ABCB1 | |
| SCHEMBL21479481 | 0.84 | ITGB3 (0.70) | ITGB3ITGAVABCG2ABCC1NCF1 | |
| SCHEMBL23868262 | 0.82 | ITGB3 (0.71) | ITGB3ITGAVABCG2ABCC1ABCB1 | |
| SCHEMBL21100942 | 0.81 | ITGB3 (0.70) | ITGB3ITGAVABCG2ABCC1ABCB1 | |
| SCHEMBL21064809 | 0.80 | ITGB3 (0.77) | ITGB3ITGAVABCG2NCF1 | |
| SCHEMBL21100867 | 0.79 | ITGB3 (0.46) | ITGB3ITGAV | |
| SCHEMBL23709862 | 0.79 | ITGB3 (0.42) | ITGB3ITGAV | |
| SCHEMBL21101051 | 0.79 | ITGB3 (0.46) | ITGB3ITGAV | |
| SCHEMBL19677591 | 0.74 | ITGB3 (0.71) | ITGB3ITGAVNCF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11077082-B2 | Composition and method for dual targeting in treatment of neuroendocrine tumors | NANOPHARMACEUTICALS, LLC (US) | 2021-08-03 | — | — | US | disclosed |
| US-20190314314-A1 | COMPOSITION AND METHOD FOR DUAL TARGETING IN TREATMENT OF NEUROENDOCRINE TUMORS | NANOPHARMACEUTICALS, LLC | 2019-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190314314-A1 | COMPOSITION AND METHOD FOR DUAL TARGETING IN TREATMENT OF NEUROENDOCRINE TUMORS | THRB, TSHR, SLC6A2 | ITGB3 12/4885ITGAV 14/4885ABCG2 673/4885 |
| US-11077082-B2 | Composition and method for dual targeting in treatment of neuroendocrine tumors | THRB, TSHR, SLC6A2 | ITGB3 12/4885ITGAV 14/4885ABCG2 673/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.